share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)

SC 13G/A:超過5%持股股東披露文件(修正)-Armistice Capital, LLC(4.99%),Steven Boyd(4.99%)
美股SEC公告 ·  2024/11/14 12:57

Moomoo AI 已提取核心訊息

On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of 180 Life Sciences Corp. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 53,935 shares, representing 4.99% of the company's class of securities. This stake is held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The filing also stated that as of the date of the filing, Armistice Capital and Boyd ceased to be the beneficial owners of more than five percent of the class of securities. The Master Fund retains the right to receive dividends or proceeds from the sale of these securities. The filing was completed in accordance with the SEC's rules and regulations, and the information provided was certified as true and correct by Steven Boyd on November 14, 2024.
On September 30, 2024, Armistice Capital, LLC and its managing member Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of 180 Life Sciences Corp. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 53,935 shares, representing 4.99% of the company's class of securities. This stake is held by the Master Fund, which is managed by Armistice Capital under an Investment Management Agreement. The filing also stated that as of the date of the filing, Armistice Capital and Boyd ceased to be the beneficial owners of more than five percent of the class of securities. The Master Fund retains the right to receive dividends or proceeds from the sale of these securities. The filing was completed in accordance with the SEC's rules and regulations, and the information provided was certified as true and correct by Steven Boyd on November 14, 2024.
2024年9月30日,Armistice Capital,LLC及其控股成員Steven Boyd向美國證券交易委員會提交了修訂後的13G/A表格,顯示其持有180 Life Sciences Corp.普通股的持股變動。報告顯示,Armistice Capital和Boyd個人分別對53,935股股份享有共同的投票權和處置權,佔公司證券類別的4.99%。這一股權由Master Fund持有,由Armistice Capital根據投資管理協議進行管理。報告還指出,截至報告日期,Armistice Capital和Boyd已不再是該類證券五分之一以上的實益所有人。Master Fund保留了收取分紅或出售這些證券所得款項的權利。該報告是根據SEC的規定完成的,Steven Boyd於2024年11月14日已確保提供的信息真實無誤。
2024年9月30日,Armistice Capital,LLC及其控股成員Steven Boyd向美國證券交易委員會提交了修訂後的13G/A表格,顯示其持有180 Life Sciences Corp.普通股的持股變動。報告顯示,Armistice Capital和Boyd個人分別對53,935股股份享有共同的投票權和處置權,佔公司證券類別的4.99%。這一股權由Master Fund持有,由Armistice Capital根據投資管理協議進行管理。報告還指出,截至報告日期,Armistice Capital和Boyd已不再是該類證券五分之一以上的實益所有人。Master Fund保留了收取分紅或出售這些證券所得款項的權利。該報告是根據SEC的規定完成的,Steven Boyd於2024年11月14日已確保提供的信息真實無誤。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息